Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/152515
|
| Title: | 以策略觀點探討高科技醫療設備採購: 以 S 醫院放射腫瘤科為例
The procurement of high-tech medical equipment from a strategic perspective: The example of the radiation oncology department in S hospital |
| Authors: | 吳佳興
Wu, Jia-Shing |
| Contributors: | 彭朱如
Peng, Tzu-Ju
吳佳興
Wu, Jia-Shing |
| Keywords: | 事業策略
放射治療
高科技醫療設備採購
Business strategy
Radiotherapy
High-tech medical equipment procurement |
| Date: | 2024 |
| Issue Date: | 2024-08-05 12:34:58 (UTC+8) |
| Abstract: | 隨著科技進步，癌症治療的高價值醫療設備不斷推陳出新，此為病人帶來 新希望，對醫療從業人員也帶來新機會。然而醫院是否投資於高價的新科技決策 相當不容易。放射治療使用的加速器在所有醫療器材中屬於相當昂貴的設備，本 研究試圖從策略的觀點討論投資貴重儀器設備時應考慮的事項。本研究以個案研 究方法，經由文獻回顧，蒐集個案醫院「放射腫瘤科」之營運資料及設備利用率， 並比較衛福部公開資料如癌症登記，瞭解個案部門目前概況，與台灣其他醫院以 及世界各國比較。本研究以事業策略形態六大構面出發，理解個案醫院其過去到 目前的策略形態，過去的競爭優勢與目前的挑戰。比較各種設備採購方案對於支 持醫院及部門營運策略可能的影響。本研究發現，策略形態六大構面具邏輯性且 面面俱到的思維模式，可以幫助我們做出較高品質的決策。由於不同的內部條件 與外在環境，不同的醫院或決策者在不同的時間點可能做出不同的選擇。本文結 論不一定適用於所有醫院，但分析邏輯可供參考。
The medical industry is constantly being revolutionized by new equipment as technology advances. This brings new hope for patients and new opportunities for healthcare professionals. However, the decision as whether to invest in costly new technologies is sometimes not easy. Accelerators for radiation therapy are among the most expensive of all medical devices. This study attempts to discuss the issues that should be considered when investing in expensive equipment from a strategic point of view. Using a case study methodology, the study was conducted by reviewing the literature, collecting information on the operation and utilization rate of the Radiation Oncology Department of the case hospital, and comparing the information published by the Ministry of Health and Welfare (MOHW), such as cancer registries, to understand the current situation of the case department, and to compare it with that of other hospitals in Taiwan and other countries around the world. Starting from six dimensions of business strategy, this study revealed the past to present strategy, past competitive advantages and current challenges of the Radiation Oncology Department in the case hospital. This study compared the possible impacts on strategy after organizing the various purchasing options. The results demonstrate that a logical and comprehensive way of thinking about the six dimensions of the strategic landscape can help us to make higher quality decisions. Different hospitals or decision makers may make different choices at different points in time due to different internal conditions and external environments. The conclusions of this article may not be applicable to all hospitals, however, the methodology and analytical logics can be used as a reference. |
| Reference: | 司徒達賢(2016)，策略管理新論:觀念架構與分析方法(三版)，臺北:智勝文 化事業有限公司。
中華民國衛生福利部統計處(2022)，醫事機構服務量統計年報。
台灣癌症登記中心(2021)，癌症登記年度報告/癌症期別與治療分析年度報告。 鄭閔聲 (2020)，「論質支付」減少無效醫療與浪費，以醫療結果作支付依據存活率愈高醫院收入愈好，今週刊。上網日期 2024 年 05 月 08 日，檢自: https://www.businesstoday.com.tw/article/category/183021/post/202010070018/
中央健康保險署(2014)，TW-DRGs 住院診斷關聯群 提高醫療品質、效率及公平性，上網日期 2024 年 04 月 28 日，檢自:https://www.mohw.gov.tw/fp-3202- 21971-1.html
財團法人國家衛生研究院(2018)，癌症診療品質認證作業計畫:認證簡介，上網日期 2024 年 04 月 28 日，檢自:https://accredit.nhri.edu.tw/intro/
台灣癌症防治網，癌症診療品質認證簡介，上網日期 2024 年 04 月 28 日，檢自:http://web.tccf.org.tw/lib/addon.php?act=post&id=2847
國民健康署(2024)，癌症就醫好選擇 癌症診療品質認證醫院來相挺，上網日期 2024 年 05 月 27 日，檢自 https://www.mohw.gov.tw/cp-16-78073-1.html
Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP. (2014). Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiotherapy and Oncology, 112(1): 140-144
Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ. (2014). Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA, 312(23): 2542-2550
Boero IJ, Gillespie EF, Hou J, Paravati AJ, Kim E, Einck JP, Yashar C, Mell LK, Murphy JD. (2017). The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer. International Journal of Radiation Oncology, Biology, Physics, 97(3): 571-580
Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, van Eycken L, Henau K, Primic-Zakelj M, Strojan P, Trojanowski M, Dyzmann-Sroka A, Kubiak A, Gasparotto C, Defourny N, Malicki J, Dunscombe P, Coffey M, Lievens Y. (2015a). The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiotherapy and Oncology, 116(1): 45-50
Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, Gasparotto C, Defourny N, Barton M, Verhoeven R, van Eycken L, Primic-Zakelj M, Trojanowski M, Strojan P, Grau C. (2015b). The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiotherapy and Oncology, 116(1): 38-44
Castelluccia A, Mincarone P, Tumolo MR, Sabina S, Colella R, Bodini A, Tramacere F, Portaluri M, Leo CG. (2022). Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review. Int J Environ Res Public Health, 19(17): 10800
Delaney G, Jacob S, Featherstone C, Barton M. (2005). The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer, 104(6): 1129-1137
Hahn C, Kavanagh B, Bhatnagar A, Jacobson G, Lutz S, Patton C, Potters L, Steinberg M. (2014). Choosing wisely: the American Society for Radiation Oncology’s top 5 list. Pract Radiat Oncol, 4(6): 349-355
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, START TG. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol, 14(11): 1086-1094
Hinrichs-Krapels S, Ditewig B, Boulding H, Chalkidou A, Erskine J, Shokraneh F. (2022). Purchasing high-cost medical devices and equipment in hospitals: a systematic review. BMJ Open, 12(9): e057516
Howard TP, McClelland S, Jimenez RB. (2024). Evolving Role of Proton Radiation Therapy in Clinical Practice. JCO Oncol Pract, OP2300674
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. (2016). Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open- label, phase 3 trial. Lancet Oncol, 17(8): 1061-1069
Medicine IO. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington (DC): National Academies Press (US); 2013
Jay Hancock KHN. (2018). Could failing proton centers be a sign of a healthcare bubble? Retrieved May 05 2024, from: https://medcitynews.com/2018/05/failing-proton- centers/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=62714921&_hsenc=p2ANqtz-90K- gQpZegiXPNF8_UiptJqrg2b1OUVhUnEXY7SQX_twSkAIUYaNuFfdnppifubPU HrCg4KMcNw82igJEgluei672ulw&_hsmi=62714921
Kesteloot K, Lievens Y, van der Schueren E. (2000). Improved management of radiotherapy departments through accurate cost data. Radiotherapy and Oncology, 55(3): 251-262
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML. (2023). Magnetic Resonance Imaging-Guided vs Computed Tomography- Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol, 9(3): 365-373
Konski A, Yu JB, Freedman G, Harrison LB, Johnstone PA. (2016). Radiation Oncology Practice: Adjusting to a New Reimbursement Model. J Oncol Pract, 12(5): e576-83
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D’Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM. (2016). Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology, 34(20): 2325-2332
Li CC, Lin YC, Liang JA, Chao KSC, Hsia TC, Chien CR. (2023). Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review. Int J Environ Res Public Health, 20(6): 4727
Li G, Xia YF, Huang YX, Okat D, Qiu B, Doyen J, Bondiau PY, Benezery K, Gao J, Qian CN. (2021). Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. BMC Cancer, 21(1): 944
Li G, Xia YF, Huang YX, Okat D, Qiu B, Doyen J, Bondiau PY, Benezery K, Gao J, Qian CN. (2022a). Cost-effectiveness of using protons for breast irradiation aiming at minimizing cardiotoxicity: A risk-stratification analysis. Front Med (Lausanne), 9: 938927
Li G, Xia YF, Huang YX, Okat D, Qiu B, Doyen J, Bondiau PY, Benezery K, Gao J, Qian CN. (2022b). Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis. Head Neck, 44(2): 431-442
Lievens Y, Borras JM, Grau C. (2015). Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. Acta Oncol, 54(9): 1275-1281
Lievens Y, Borras JM, Grau C, Aggarwal A. (2021). Value-based radiotherapy: A new chapter of the ESTRO-HERO project. Radiotherapy and Oncology, 160: 236- 239
Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM, ESTRO–HERO CC. (2020). How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol, 21(1): e42-e54
Lievens Y, Grau C, Aggarwal A. (2019). Value-based health care - what does it mean for radiotherapy. Acta Oncol, 58(10): 1328-1332
Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. (2020). Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 38(14): 1569-1579
Mackillop WJ, Kong W. (2019). Comparison of Methods for Measuring Radiotherapy Utilisation. Clin Oncol (R Coll Radiol), 31(7): e95-e101
Mailhot Vega RB, Mohammadi H, Patel SI, Holtzman AL, Lockney NA, Lynch JW, Bansal MM, Liang X, Slayton WB, Parsons SK, Hoppe BS, Mendenhall NP. (2022). Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology, Biology, Physics, 112(1): 158-166
Mee T, Kirkby NF, Defourny NN, Kirkby KJ, Burnet NG. (2023). The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (Favourable Outcomes from RadioTherapY) project. Br J Radiol, 96(1152): 20230334
Merie R, Gabriel G, Shafiq J, Vinod S, Barton M, Delaney GP. (2019). Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. Radiotherapy and Oncology, 141: 41-47
Michael Porter EOTEOT. Redefining Health Care: Creating Value-Based Competition on Results. Harvard Business School Publishing Corp (Perseus); 2006
Ming J, He Y, Yang Y, Hu M, Zhao X, Liu J, Xie Y, Wei Y, Chen Y. (2022). Health technology assessment of medical devices: current landscape, challenges, and a way forward. Cost Eff Resour Alloc, 20(1): 54
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. (2012). Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. Journal of Clinical Oncology, 30(31): 3827-3833
Norlund A, SBU SG. (2003). Costs of radiotherapy. Acta Oncol, 42(5-6): 411-415 Obremskey WT, Dail T, Jahangir AA. (2012). Value-based purchasing of medical devices. Clin Orthop Relat Res, 470(4): 1054-1064
Ocanto A, Torres L, Montijano M, Rincón D, Fernández C, Sevilla B, Gonsalves D, Teja M, Guijarro M, Glaría L, Hernánz R, Zafra-Martin J, Sanmamed N, Kishan A, Alongi F, Moghanaki D, Nagar H, Couñago F. (2024). MR-LINAC, a New Partner in Radiation Oncology: Current Landscape. Cancers (Basel), 16(2): 270
Porter ME. (2010). What is value in health care. New England Journal of Medicine, 363(26): 2477-2481
Ramsey S, Schickedanz A. (2010). How should we define value in cancer care. Oncologist, 15 Suppl 1: 1-4
Royce TJ, Qureshi MM, Truong MT. (2018). Radiotherapy Utilization and Fractionation Patterns During the First Course of Cancer Treatment in the United States From 2004 to 2014. J Am Coll Radiol, 15(11): 1558-1564
Schnipper LE, Lyman GH, Blayney DW, Hoverman JR, Raghavan D, Wollins DS, Schilsky RL. (2013). American Society of Clinical Oncology 2013 top five list in oncology. Journal of Clinical Oncology, 31(34): 4362-4370
Spencer K, Defourny N, Tunstall D, Cosgrove V, Kirkby K, Henry A, Lievens Y, Hall P. (2022). Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. Radiotherapy and Oncology, 166: 180-188
Steindl A, Brunner TJ, Heimbach K, Schweighart K, Moser GM, Niziolek HM, Moor E, Kreminger J, Starzer AM, Dieckmann K, Gatterbauer B, Widhalm G, Preusser M, Berghoff AS. (2022). Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. European Journal of Cancer, 162: 170-181
Verma V, Shah C, Rwigema JC, Solberg T, Zhu X, Simone CB. (2016). Cost-comparativeness of proton versus photon therapy. Chin Clin Oncol, 5(4): 56
Yan S, Ngoma TA, Ngwa W, Bortfeld TR. (2023). Global democratisation of proton radiotherapy. Lancet Oncol, 24(6): e245-e254
Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, Zhang Z, Zheng J, Steckler A, Bucwinska W, Bernstein A, Betof Warner A, Yu H, Kris MG, Seidman AD, Wilcox JA, Malani R, Lin A, DeAngelis LM, Lee NY, Powell SN, Boire A. (2022). Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. Journal of Clinical Oncology, JCO2201148 |
| Description: | 碩士
國立政治大學
經營管理碩士學程(EMBA)
110932154 |
| Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0110932154 |
| Data Type: | thesis |
| Appears in Collections: | [經營管理碩士學程EMBA] 學位論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 215401.pdf | | 2870Kb | Adobe PDF | 0 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
